Apogee Therapeutics Analysis: Zumilokibart in Atopic Dermatitis

Apogee Therapeutics (APGE) reported solid 1Q26 earnings and reaffirmed timelines for zumilokibart, their long-acting anti-IL13 antibody targeting the $24bn atopic dermatitis market. The drug offers a competitive profile with significantly less frequent dosing (every 3-6 months) compared to current market leaders.

Key Takeaways

• 1.Zumilokibart (anti-IL13) demonstrated competitive efficacy and safety in moderate-to-severe atopic dermatitis (AD) vs. standards-of-care, with a potentially superior Q3M/Q6M dosing regimen.
• 2.Management expects Ph2 Part B 16-week data in 2Q26 to inform dose selection for Phase 3 studies in atopic dermatitis.
• 3.APGE is well-capitalized with $1.3bn in cash, providing a runway into 2029 through its planned BLA filing.

Table of Contents

• Ph2 Part B 16-week zumilokibart data in moderate-to-severe atopic dermatitis on track for 2Q
• Ph1b combination IL-13 and OX40L (APG279) data from a head-to-head study versus Dupixent is expected in 2H
• Post interim Ph1b data for zumilokibart in mild-to-moderate asthma in early-2026, we anticipate further details on the development path in asthma and EoE this year
• Cash runway into 2029
• Valuation and Risks
• Disclosure Appendix
• Price target and rating history chart(s)
• Regulatory disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial